Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas

Malignant Gliomas Clinical Trial

— IRUSZACT0073  

Official title:

A Phase I Dose Escalation Study of Vandetanib (ZACTIMA, ZD6474) With Hypofractionated Stereotactic Radiotherapy in Patients With Recurrent Malignant Gliomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00822887
• Other study ID #: 06-0870.cc
• Status: Completed
• Phase: Phase 1
• First received: January 13, 2009
• Last updated: June 24, 2013
• Start date: March 2007
• Est. completion date: January 2011

Study information

• Verified date: June 2013
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to find out the highest dose of vandetanib that can be safely given with repeat radiation therapy.

This study drug has been designed to block certain chemical pathways that stimulate tumor to grow. The study drug has been shown to slow the growth of a number of types of cancers.

This will be a dose escalation study. A dose escalation study means that successive groups of patients will receive higher doses of the study drug. There are three dose levels. The dose of the study drug received will depend on the stage the study has reached at the time a patient decides to participate.

In addition to taking the study drug patients will also receive radiation therapy to the brain tumor for 3 days.

Hypothesis The objective of this study is to determine the maximally tolerated dose (MTD) of VANDETANIB given with 36 Gy hypofractionated stereotactic radiotherapy. The MTD will be dose of VANDETANIB at which no patients develop acute grade 5 toxicity and less than 30% of patients develop acute (within 30 days of radiation therapy) or delayed (at least 30 days after radiation completed) dose limiting toxicities.

Description:

Screening Prior to receiving any treatment, tests will be performed to determine overall medical condition. This will include blood tests, questions about medical history, and physical and neurological exams.

MRI scan of the brain, electrocardiogram (ECG) and chest X-ray will be performed as baseline studies if they have not been performed in the last 28 days.

Women of child-bearing potential will also have a serum pregnancy test within 2 days before taking the study drug.

During treatment If all of the study criteria are met and subject is enrolled in the study, you will start taking the study drug at least 7 days before radiation therapy. You will take the study drug once a day by mouth. You should take the study drug at about the same time each day. If you forget to take a dose, take the missed dose as soon as you remember, as long as it is at least 12 hours before the next dose is due. If it is less than 12 hours until the next dose, do not take the dose you have missed. If you throw up within 30 minutes after you take the study drug, you should take another dose, and use medicine to stop or relieve your vomiting per your doctor's instruction. You will continue to take the study drug for a total duration of one year. The study will be stopped if your disease progresses or there is excessive toxicity. Your participation in the study will be for one year. However, we will continue to follow your disease status, general health and possible treatment-related side effects after one year and for as long as possible.

This is a Phase I study. These types of studies usually include a small number of subjects and are often called dose-escalation studies. Subjects in the first dose group will be receiving a small dose of the study drug. If no unacceptable side effects are observed in these subjects, the next group of subjects will receive the next higher dose of study drug. The study drug doses planned are as follows:

Dose Level Drug dose Level 1 100 mg once a day Level 2 200 mg once a day Level 3 300 mg once a day

You will be assigned to one of three levels depending on when you enter the study.

You will also receive radiation therapy. The radiation dose is the same for all patients. Radiation therapy will begin at least 7 days after you begin taking the study drug. The radiation therapy will be once a day for 3 consecutive days. A special plastic mask will be made for you and used to hold your head still during each radiation treatment.

Tests and procedures will be performed throughout your treatment to determine how your cancer is responding and to monitor you for safety purposes. The tests and procedures will be scheduled for you. The following tests and procedures will be performed:

• Physical examination, neurological examination, and ECG, right before, and in the first, second, fourth, eighth and twelfth week of drug treatment; then once every three months.

• Brain MRI and quality of life questionnaires at one month and three month after radiation therapy, then once every three months.

• Chest X-ray as your doctor determines.

Follow-up You will also have follow-up visits with your doctor once a month for the first 6 months, then once every three months. You may also see your doctor anytime as needed.

Duration You will be on this study for up to 12 months.

Other known NCT identifiers

• NCT00721292

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: January 2011
• Est. primary completion date: May 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with histopathologically confirmed malignant gliomas that recurred after surgical resection and conventional radiation therapy

• Tumor is not located in the eloquent part of the brain and not touching the brainstem, optic chiasm or optic nerve so that these critical structures will not receive full dose of re-irradiation

• Recurrent tumor is not surgically resectable or patient is not medically operable

• Age > 18 years.

• Radiographical evidence of local recurrence on brain MRI, with or without histopathological confirmation.

• Estimated survival of at least 3 months

• Zubrod Performance Scale of 0-2

• Hgb greater than 10 gm/dl, absolute neutrophil count greater than 1500/ul, platelets greater than 100,000/ul, blood urea nitrogen (BUN) less than 25 mg/dl, Bilirubin less than 2.0 mg/dl, serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) less than 2 x normal range

• Less than or equal to 3 recurrent tumors, and combined largest diameter of all tumors less than or equal to 6 cm

• Single recurrent tumor less than or equal to 6 cm in the largest diameter

Exclusion Criteria:

• Prior therapy with any anti-Epidermal growth factor receptor(EGFR) and/or anti-VEGFR therapies

• Recurrent tumor greater than 6 cm in the largest diameter

• Recurrent tumor located in the brainstem.

• Prior radiation therapy to the brain within 2 months.

• Evidence of severe or uncontrolled systemic disease or any concurrent condition (such as severe cognitive impairment)

• pregnant and breast-feeding women will be excluded

• Treated on any other clinical protocols or with a non-approved or investigational drug within 30 days before Day 1 of study treatment.

• Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded)

• Clinically significant cardiac event

• History of arrhythmia. Atrial fibrillation, controlled on medication is not excluded.

• Previous history of corrected electrocardiogram QT interval (QTc)prolongation as a result from other medication that required discontinuation of that medication.

• Congenital long QT syndrome, or 1st degree relative with unexplained sudden death under 40 years of age

• Presence of left bundle branch block QTc with Bazett's correction that is unmeasurable, or 480 msec on screening ECG. If a patient has QTc 480 msec on screening ECG, the screen ECG may be repeated twice (at least 24 hours apart). The average QTc from the three screening ECGs must be less than 480 msec in order for the patient to be eligible for the study.

• Concomitant medication that may cause QTc prolongation, induce Torsades de Pointes or induce cytochrome P450 3A4 (CYP3A4) function Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg)

• Active diarrhea that may affect the ability of the patient to absorb the VANDETANIB.

• Major surgery within 4 weeks, or incompletely healed surgical incision before starting study therapy

• Clinical and/or radiographic evidence of bleeding in the recurrent brain tumor.

• Patients currently on enzyme inducing anticonvulsants. However, patients are eligible if the enzyme inducing anticonvulsants can be discontinued or switched to non- enzyme inducing anticonvulsants one week before study entry. Non-enzyme inducing anticonvulsants cannot be those which may cause QTc prolongation, induce Torsades de Pointes or induce CYP3A4 function

• Laboratory results:

• Serum bilirubin greater than 1.5 x the upper limit of reference range (ULRR)

• Serum creatinine greater than 1.5 x ULRR or creatinine clearance less than 50 mL/minute (calculated by Cockcroft-Gault formula)

• Potassium, less than 4.0 mmol/L despite supplementation; serum calcium (ionized or adjusted for albumin,) or magnesium out of normal range despite supplementation

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.5 X ULRR

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glioma
• Malignant Gliomas

Intervention

Drug:
• Vandetanib
Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd

Radiation:
• Fractionated Stereotactic Radiotherapy
All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.

Locations

Country	Name	City	State
United States	University of Colorado Health Science Center	Aurora	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
University of Colorado, Denver	AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of acute and delayed = grade 3 Central nervous system (CNS) toxicity by Common Terminology Criteria (CTC) v.3.		12 months.	Yes
Secondary	Incidence of acute and delayed = grade 3 non-CNS toxicity		12 months.	Yes
Secondary	Progression-free survival at 6 months		12 months.	Yes
Secondary	Overall survival		12 months.	Yes
Secondary	Objective response rate		12 months.	Yes
Secondary	Quality of survival		12 months.	Yes